I
IMMUNOVANT INC
NASDAQ: IMVT (Immunovant, Inc.)
Kemas kini terakhir: 4 jam lalu27.12
-0.02 (-0.09%)
| Penutupan Terdahulu | 27.15 |
| Buka | 27.23 |
| Jumlah Dagangan | 902,063 |
| Purata Dagangan (3B) | 1,430,198 |
| Modal Pasaran | 5,519,792,640 |
| Harga / Buku (P/B) | 6.05 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 May 2026 |
| EPS Cair (TTM) | -2.73 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.01% |
| Nisbah Semasa (MRQ) | 11.16 |
| Aliran Tunai Operasi (OCF TTM) | -375.87 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -227.82 M |
| Pulangan Atas Aset (ROA TTM) | -37.97% |
| Pulangan Atas Ekuiti (ROE TTM) | -62.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Immunovant, Inc. | Menaik | Menurun |
AISkor Stockmoo
1.0
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.00 |
|
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 58.17% |
| % Dimiliki oleh Institusi | 55.78% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Deep Track Capital, Lp | 31 Dec 2025 | 11,526,971 |
| Armistice Capital, Llc | 31 Dec 2025 | 5,747,155 |
| Two Seas Capital Lp | 31 Dec 2025 | 2,866,962 |
| Alpine Global Management, Llc | 31 Dec 2025 | 2,626,692 |
| Adar1 Capital Management, Llc | 31 Dec 2025 | 2,480,968 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 44.00 (Guggenheim, 62.24%) | Beli |
| Median | 39.50 (45.65%) | |
| Rendah | 35.00 (HC Wainwright & Co., 29.06%) | Beli |
| Purata | 39.50 (45.65%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 27.09 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Feb 2026 | 35.00 (29.06%) | Beli | 26.68 |
| Guggenheim | 09 Feb 2026 | 44.00 (62.24%) | Beli | 27.49 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| GIRAO TIAGO | - | 28.91 | -25,760 | -744,722 |
| STOUT JAY S | - | 28.91 | -2,754 | -79,618 |
| Jumlah Keseluruhan Kuantiti Bersih | -28,514 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -824,340 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 28.91 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| STOUT JAY S | Pegawai | 23 Apr 2026 | Jual (-) | 2,754 | 28.91 | 79,618 |
| GIRAO TIAGO | Pegawai | 23 Apr 2026 | Jual (-) | 25,760 | 28.91 | 744,722 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Feb 2026 | Pengumuman | Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |